- Home
- SIBN vs RGNX Comparison
SIBN vs RGNX Comparison
Compare SIBN & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIBN | RGNX |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.1M | 661.2M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SIBN | RGNX |
|---|---|---|
| Price | $18.45 | $13.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $24.33 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 627.2K | 626.9K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,578,000.00 | $161,318,000.00 |
| Revenue This Year | $21.44 | $132.80 |
| Revenue Next Year | $15.30 | $48.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.27 | ★ 91.30 |
| 52 Week Low | $12.50 | $5.04 |
| 52 Week High | $20.05 | $14.24 |
Technical Indicators
Market Signals| Indicator | SIBN | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 63.67 |
| Support Level | $18.99 | $12.69 |
| Resistance Level | $19.44 | $13.42 |
| Average True Range (ATR) | 0.61 | 0.86 |
| MACD | -0.22 | 0.10 |
| Stochastic Oscillator | 6.02 | 64.63 |
Price Performance
Historical ComparisonAbout SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.